Primary care doctors have expressed concerns about telehealth companies' expanding role in prescribing obesity medications, citing potential conflicts between providing medical care and controlling drug costs. Insurance companies increasingly require patients to use specific telehealth platforms before approving prescriptions for GLP-1 drugs.